| Drug Name | Novorm(Repaglinide) |
|---|---|
| Drug Class |
Anti-diabetic
|
| Risk minimization type |
Safety communication
|
| Specialty (Theraputic area) |
Endocrine
|
| Risk |
risk of decrease in blood glucose level that may be associated with the use of repaglinide and clopidogrel |
| safety communication |
|